Related Experiment Video

Updated: Jan 17, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.6K

Immunotherapy in gastric adenocarcinoma - a rapidly evolving treatment landscape

Yang Wang1, Geoffrey Chong2

  • 1Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia; Department of Medical Oncology, Northern Health, Epping, Australia.

Critical Reviews in Oncology/Hematology
|September 15, 2025
PubMed

Insights

Gastric cancer (GC) is a leading cause of cancer death globally. This review details immunotherapy use, biomarkers, and novel treatments for gastric and gastroesophageal junction cancers, offering hope for improved patient outcomes.

Area of Science:

  • Oncology
  • Immunotherapy
  • Gastroenterology

Background:

  • Gastric cancer (GC) is a significant global health challenge with poor patient prognosis.
  • Despite treatment advancements, effective therapies for advanced stages are limited.
  • Immunotherapy, particularly immune checkpoint inhibitors, shows promise in treating GC and gastroesophageal junction (GEJ) adenocarcinomas.

Purpose of the Study:

  • To review the molecular subtypes of gastric cancer.
  • To summarize the evidence for immunotherapy in early and advanced GC/GEJ.
  • To discuss biomarkers and novel immunotherapeutics for GC treatment.

Main Methods:

  • Literature review of clinical trials and studies on gastric cancer treatment.
  • Analysis of data regarding immunotherapy efficacy in different stages of GC/GEJ.
  • Exploration of current and emerging biomarkers and therapeutic strategies.

Main Results:

  • Immunotherapy is increasingly used across all treatment settings for GC/GEJ.
  • Evidence supports immunotherapy in perioperative settings for early-stage disease.
  • Combination therapies with chemotherapy and targeted agents are effective in metastatic disease.

Conclusions:

  • Immunotherapy represents a crucial advancement in gastric cancer treatment.
  • Understanding molecular subtypes and biomarkers is key to optimizing immunotherapy.
  • Novel immunotherapeutics hold potential for improving survival in GC patients.
Keywords:
BiomarkerBispecific antibodiesCAR-TGastric cancerImmunotherapy

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.5K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.7K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
974
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K